T1	Person 0 4	Aged
T2	Value 5 34	5 years to less than 12 years
T3	Temporal 35 45	at Visit 1
T4	Reference_point 38 45	Visit 1
R1	Has_index Arg1:T3 Arg2:T4	
R2	Has_value Arg1:T1 Arg2:T2	
R3	Has_temporal Arg1:T2 Arg2:T3	
T6	Person 142 146	Male
T7	Person 150 164	pre-menarchial
T8	Person 165 171	female
T9	Scope 150 171	pre-menarchial female
*	OR T9 T6
T10	Person 200 214	pre-adolescent
T11	Condition 227 243	signs of puberty
T12	Negation 215 226	without any
R4	Has_negation Arg1:T11 Arg2:T12	
T13	Measurement 245 257	Tanner Stage
T14	Value 258 259	1
R5	Has_value Arg1:T13 Arg2:T14	
T15	Scope 215 243	without any signs of puberty
R6	Subsumes Arg1:T15 Arg2:T13	
T16	Measurement 286 292	height
T17	Value 263 275	Normal range
T18	Measurement 297 303	weight
R7	Has_value Arg1:T16 Arg2:T17	
R8	Has_value Arg1:T18 Arg2:T17	
T19	Measurement 305 311	Weight
T21	Measurement 316 322	height
T22	Value 348 381	within the percentile range 3-97%
T5	Not_a_criteria 47 140	At least 15 (25%) children of the total study population must be aged 5 to less than 8 years.
T20	Condition 474 491	persistent asthma
T23	Qualifier 493 540	as defined by the National Institutes of Health
R9	Has_qualifier Arg1:T20 Arg2:T23	
T24	Temporal 545 591	at least 3 months prior to the Screening Visit
T25	Reference_point 576 591	Screening Visit
R10	Has_index Arg1:T24 Arg2:T25	
T26	Qualifier 596 615	pre-bronchodilatory
T27	Measurement 616 657	forced expiratory flow in 1 second (FEV1)
T28	Temporal 658 680	at Visit 1 (Screening)
T29	Reference_point 661 680	Visit 1 (Screening)
T30	Value 681 696	>=80% predicted
R11	Has_value Arg1:T27 Arg2:T30	
R12	Has_temporal Arg1:T27 Arg2:T28	
R13	Has_qualifier Arg1:T27 Arg2:T26	
T31	Drug 717 749	Short acting beta-agonist (SABA)
T32	Temporal 754 788	within 4 hours of this measurement
T33	Reference_point 772 788	this measurement
R14	Has_index Arg1:T32 Arg2:T33	
R15	Has_temporal Arg1:T31 Arg2:T32	
T34	Negation 714 716	no
R16	Has_negation Arg1:T31 Arg2:T34	
T35	Procedure 818 834	asthma therapies
T36	Temporal 835 864	prior to entry into the study
T37	Reference_point 844 864	entry into the study
R17	Has_index Arg1:T36 Arg2:T37	
R18	Has_temporal Arg1:T35 Arg2:T36	
T38	Drug 866 878	SABA inhaler
T39	Drug 891 901	salbutamol
R19	Subsumes Arg1:T38 Arg2:T39	
T40	Drug 1027 1059	leukotriene receptor antagonists
T41	Drug 1015 1023	cromones
*	OR T41 T40 T42
T42	Drug 1092 1095	ICS
T43	Drug 1119 1129	budesonide
T44	Value 1130 1152	<=400 micrograms (mcg)
R20	Has_value Arg1:T43 Arg2:T44	
R21	Subsumes Arg1:T42 Arg2:T43	
T45	Scope 866 1170	SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <=400 micrograms (mcg) total daily dose)
R22	Subsumes Arg1:T35 Arg2:T45	
T46	Procedure 1189 1192	ICS
T47	Negation 1186 1188	no
R23	Has_negation Arg1:T46 Arg2:T47	
T48	Temporal 1197 1234	within 2 weeks of Visit 1 (Screening)
T49	Reference_point 1215 1234	Visit 1 (Screening)
R24	Has_index Arg1:T48 Arg2:T49	
R25	Has_temporal Arg1:T46 Arg2:T48	
T50	Drug 1267 1271	SABA
T51	Drug 1302 1313	rescue SABA
T52	Subjective_judgement 1237 1382	Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study.
T53	Non-query-able 1237 1382	Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study.
T54	Non-query-able 1384 1719	Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement.
T55	Post-eligibility 1384 1719	Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement.
T56	Subjective_judgement 1720 1939	The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC).
T57	Non-query-able 1720 1939	The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC).
T58	Post-eligibility 1720 1939	The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC).
T59	Not_a_criteria 1940 2057	(2) Subject and their legal guardian(s) understand that the study requires them to be treated on an outpatient basis.
T60	Non-query-able 2058 2315	(3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call.
T61	Subjective_judgement 2058 2315	(3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call.
